Skip to Main Content
Click to read notice

All Trillium Health locations will be closed Wednesday, June 19 for Juneteenth.

main page headline goes here, size is h2

Paragraph 4: At Trillium Health, we believe everyone should have access to health care, regardless of income or any other factor. That is why we offer several different ways to help make sure you are cared for, no matter what your financial situation may be. This is a free and confidential service offered to the community.

recent studies

  • Otitis Treatment With OtoSight™ - Modification of Antibiotic Treatment Intervention in Children (OTO-MATIC) Sponsored by PhotoniCare Inc. 

  • Real World Community-Based HIV Rapid Start Antiretroviral with BFTAF versus Conventional HIV Antiretrovial Therapy start - The RoCHaCHa Study, A pilot study. Investigator initiated collaboration with Gilead Sciences 

  • Observational Cohort Study of Cabenuva Utilization, Outcomes, and Patient Experience in the United States (BEYOND). Sponsored by ViiV Healthcare 

  • A Phase 4, Randomized, Open-label, Two-arm Study Evaluating Implementation Strategies for the Delivery of Cabotegravir in Low and High-volume Pre-exposure Prophylaxis (PrEP) Sites in the U.S. for HIV Uninfected MSM and Transgender Men ≥ 18 (PILLAR). Sponsored by ViiV Healthcare

presentations and publications

  • Valenti WM, Phoenix J, Patel R, et al. Integrating Long-acting Injectable Cabotegravir for PrEP into Standard of Care for Cisgender Women, Transgender Women, Transgender Men, and Men Who Have Sex with Men: Results from the PILLAR & EBONI Studies, Poster 1547 presented at IDWeek 2023, October 11-15, 2023, Boston, MA. Access at https://doi.org/10.1093/ofid/ofad500.1382 

  • Dandachi D, Cunningham D, Valenti WM, et al. Perspectives of People with HIV (PWH) 6 Months Following a Switch to Cabotegravir and Rilpivirine Long-acting (CAB+RPV LA) in an Observational Real-world US Study (BEYOND), Poster 1567, IDWeek 2023, October 11-15, 2023, Boston, MA. Access at https://doi.org/10.1093/ofid/ofad500.1402 

  • Zuppelli AR, Scutaru J, Danforth A, et al. Interim Analysis of Real-World Community-Based HIV Rapid Start Antiretroviral with BFTAF Versus Conventional HIV Antiretroviral Therapy Start – The RoCHaCHa Study, A Pilot Study. Poster 880 presented at IDWeek 2021, September 29- October 3, 2021, Virtual conference. Access at https://doi.org/10.1093/ofid/ofab466.1075 

  • Zuppelli AR, Mancenido M, Scutaru J, et al. Real World Community-Based HIV Rapid Start Antiretroviral with BFTAF Versus Conventional HIV Antiretroviral Therapy Start – The RoCHaCHa Study, a Pilot Study, Poster 1039 presented at IDWeek 2020, October 21-25, 2020, Virtual conference. Access at https://doi.org/10.1093/ofid/ofaa439.1225 

  • Braksmaier A, McMahon J, Chen SR, et al. Willingness to Take PrEP for HIV Prevention: The Combined Effects of Race/Ethnicity and Provider Trust. AIDS Education and Prevention. 2018; 30: 1 12.  https://guilfordjournals.com/doi/abs/10.1521/aeap.2018.30.1.1?af=R&